Grifols reported EUR680.58M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.49M 108K Jun/2026
Arca Biopharma USD 50.17M 1.45M Mar/2026
aTyr Pharma USD 63.76M 765K Jun/2026
Bio Path USD 9.34M 100K Mar/2026
Brainstorm Cell Therapeutics USD 11.04M 0 Mar/2026
Capricor Therapeutics USD 57.37M 11.65M Dec/2025
Cara Therapeutics USD 9.38M 2.01K Mar/2026
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Grifols EUR 680.58M 846.11K Dec/2025
Immunic USD 120.38M 21.73M Dec/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
TherapeuticsMD USD 11K 0 Sep/2023